Roland Diggelmann resigns as CEO of Roche Diagnostics after 10 years

By Sophie Chapman
Share
The Chief Executive Officer of the Swizerland-based drugmaker, Roche Diagnostics, has announced his resignation. Ronald Diggelmann will leave the compa...

The Chief Executive Officer of the Swizerland-based drugmaker, Roche Diagnostics, has announced his resignation.

Ronald Diggelmann will leave the company next month following working for the firm for a decade.

The CEO, 51, joined Roche Diagnostics’ parent company, Roche, in 2008. Digglemann has worked for the diagnostics unit since 2012.

Prior to his role as CEO, Diggelmann was appoint as the Region Head of Asia Pacific for Roche Diagnostics.

Michael Heuer, the firm’s Region Head of Europe, Middle East, Africa, and Latin America, will be appoint the interim CEO in September.

SEE ALSO:

“I am grateful to Roland Diggelmann for his many valuable contributions during his 10 years at Roche and I wish him all the best for the future,” stated Severin Schwan, CEO of Roche.

“I am pleased to appoint Michael Heuer as interim CEO of our Diagnostics Division.”

“Michael is a very respected leader with a wealth of experience in diagnostics.”

Heuer has worked in sales, marketing, and product develop positions in Europe and the US.

The soon-to-be CEO has also held the position of Head of Roche Near Patient Testing Business Area.

Share

Featured Articles

NTT & Olympus: World's First Cloud Endoscopy System

NTT and medical technology company Olympus put on a demonstration, showing the IOWN APN's low-latency capability, for the first cloud endoscopy system

Richter BioLogics' New Biopharmaceutical GMP Facility

Richter BioLogics GmbH & Co KG's a new biopharmaceutical GMP facility in Germany will boost production capabilities and local employment

GE HealthCare's Pilot Study Shows Value of Portrait Mobile

A pilot study from GE Healthcare has shown the value of Portrait Mobile Continuous Monitoring Solution, a leap in post-surgical monitoring efficiency

50% of Teens to be Affected by Myopia Globally by 2050

Telehealth & COVID-19

NVIDIA’s AI Insights for Diabetes Prevention with GluFormer

Technology & AI

Novo Nordisk's CagriSema Next Gen Weight-Loss Treatment

Medical Devices & Pharma